Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tumor-penetrating peptide for systemic targeting of Tenascin-C.

Autor: Lingasamy P; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Tobi A; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Kurm K; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Kopanchuk S; Institute of Chemistry, University of Tartu, Tartu, Estonia., Sudakov A; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.; Oxford Nanopore Technologies Ltd., Oxford, UK., Salumäe M; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Rätsep T; Department of Neurosurgery, Tartu University Hospital, Tartu, Estonia., Asser T; Department of Neurosurgery, Tartu University Hospital, Tartu, Estonia., Bjerkvig R; Department of Biomedicine Translational Cancer Research, University of Bergen, Bergen, Norway., Teesalu T; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia. tambet.teesalu@ut.ee.; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA. tambet.teesalu@ut.ee.; Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, California, USA. tambet.teesalu@ut.ee.

Publikováno v: Scientific reports [Sci Rep] 2020 Apr 02; Vol. 10 (1), pp. 5809. Date of Electronic Publication: 2020 Apr 02.